Vik

No surprises here...the revolving door policies between the regulatory agencies and pharma continues. An investigation has raised concerns about the 'cozy relationship' between the Food and Drug Association (FDA) and Moderna during the Covid pandemic. Dr. Fink who was Acting Deputy Director of the Office of Vaccines Research and Review. He was ultimately part of the decision to authorize the Pfizer-BioNTech and Moderna mRNA shots. After leaving FDA 2 months later, he took the six-figure job of Head of the Translational Medicine and Early Clinical Development within the department of infectious diseases at Moderna. Dr. Goswami held her position as Medical Officer for the FDA's Center for Biologics Evaluation and Research. She was responsible for evaluating whether clinical data produced by Moderna regarding its two-dose Covid shot met the agency’s regulatory standards for approval. In June 2022, the same month that she left the FDA, she moved on to take a position at Moderna as Director of Clinical Development in treatments and vaccines for infectious diseases. Technically FDA employees are supposed to wait one year before lobbying or having 'any communication to or appearance before any officer or employee of their former agency on behalf of anyone seeking official action.' But the BMJ probe found that because the FDA keeps no record of where employees go, Dr Doran Fink and Dr Jaya Goswami slipped through the cracks. According to the Texas Ethics Commission (just for fun): For two years after a board member or executive head leaves a regulatory agency, he or she may not appear before or communicate with officers or employees of the agency with the intent to influence the board on behalf of any person in connection with any matter on which the person seeks official action.